Chief executive officer of Satellite Bio
Dave Lennon was appointed Chief Executive Officer of Satellite Bio in July 2021. Lennon is a 20-year industry veteran driven by the purpose to bring together diverse teams to address the most pressing challenges in medicine to achieve amazing impact for patients and their families.
Prior to Satellite Bio, Lennon spent more than 15 years with Novartis working across multiple therapeutics and geographies. He was most recently President, Novartis Gene Therapies, where he led the approval and launch of Zolgensma, the first systemic gene therapy for spinal muscular atrophy that was approved in more than 40 countries.
Prior to Novartis Gene Therapies, Lennon served in positions of increasing responsibility across Oncology, Neuroscience, Transplant and Rare Disease therapeutic areas in the U.S., Europe, Japan and China. Key positions included General Manager Oncology Japan, Solid Tumor Franchise Head USA and Chief Marketing Officer China. He started his career at Novartis as Global Head, New Products and Portfolio Strategy.
Lennon earned a PhD in Molecular Medicine from Weill Cornell Medical College of Cornell University and BA in Biophysics from Columbia College of Columbia University.
Visit website: https://satellite.bio/team#DaveLennon
See also: Satellite Bio - Developing new class of regenerative medicine - Tissue therapeutics
Dave Lennon News
Satellite Bio raised $110M to push its tissue therapies to the clinic
FierceBiotech - 20-Apr-2022
Bioengineered implanatable tissues can repair or replace diseases organsRead more...